Placebo News and Research

RSS

R-Tech Ueno completes RK-023 phase I study on hypotrichosis of the eyelashes

R-Tech Ueno is pleased to announce the completion of a phase I clinical study of RK-023, a new compound that is being developed for the treatment of hypotrichosis of the eyelashes.

24 Apr 2012

Women & Infants named lead center in 14-site study of cytomegalovirus

Women & Infants Hospital of Rhode Island, through its participation in the Maternal-Fetal Medicine Units Network, has been named the lead center in a 14-site, $25 million study of cytomegalovirus (CMV), the most common infection during pregnancy.

24 Apr 2012

Autism symptoms treatment using antidepressant SSRIs may not be effective: Review

According to a new review of published and unpublished research, the belief that certain antidepressants can help to treat repetitive behaviors in kids with autism may be based on incomplete information.

24 Apr 2012

Botox injections may improve frequency of chronic daily and migraine headaches

Although botulinum toxin A injections are U.S. Food and Drug Administration approved for preventive treatment for chronic migraines, a review and analysis of previous studies finds a small to modest benefit for patients with chronic migraine headaches and chronic daily headaches, although botox injections were not associated with greater benefit than placebo for preventing episodic migraine or chronic tension-type headaches, according to an article in the April 25 issue of JAMA.

24 Apr 2012

Asubio commences SUN13837 Phase 2 clinical trial for acute spinal cord injury

Today, Asubio announced the initiation of a landmark Phase 2 clinical trial of SUN13837, an investigational medication being developed to improve neurological function in patients with newly diagnosed acute spinal cord injury.

23 Apr 2012

MicuRx completes MRX-I Phase 1 trial on MRSA and VRE infection

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the completion of its Phase 1 clinical trial for MRX-I, its first development-stage antibiotic drug candidate.

23 Apr 2012

Estrone provides anti-inflammatory and antioxidant capabilities after TBI

With more than 1.7 million people sustaining a traumatic brain injury each year, the need to identify processes to limit inflammation and subsequent damage is critical. Approximately 275,000 people are hospitalized annually with traumatic brain injury, leaving 85,000 with long-term disabilities and taking the lives of more than 50,000. More than 5 million people live with disabilities caused by traumatic brain injuries, often the result of car accidents and falls. Direct and indirect costs exceed $75 billion.

23 Apr 2012

New drug can prevent exacerbations of asthma due to common cold: Trial report

For the tens of thousands of asthma sufferers in the UK there is a “breakthrough” drug that reduces complications caused by the common cold, it is claimed.

22 Apr 2012

Large doses of vitamin C may moderately reduce blood pressure

Taking large doses of vitamin C may moderately reduce blood pressure, according to an analysis of years of research by Johns Hopkins scientists. But the researchers stopped short of suggesting people load up on supplements.

21 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

Researchers revisit Charcot's vibration therapy for Parkinson's disease

In the 19th century, Jean-Martin Charcot, the celebrated neurologist, developed a "vibration chair," to relieve symptoms of Parkinson's disease. Charcot reported improvements in his patients, but he died shortly thereafter and a more complete evaluation of the therapy was never conducted.

20 Apr 2012

New data provides hope for HCV non-responders

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.

20 Apr 2012

Interferon beta-1a shows promise against MS

People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program at the American Academy of Neurology's 64th Annual Meeting in New Orleans, April 21 to April 28, 2012.

20 Apr 2012

Positive data from Synairgen’s SNG001 Phase II trial on asthma

Scientists from the University of Southampton and Synairgen, a respiratory drug development company spun out from the University, can announce positive data from its Phase II clinical trial, into the effectiveness of the drug SNG001 (inhaled interferon beta) for asthma patients.

20 Apr 2012

SK Biopharmaceuticals receives FDA Orphan Drug status for carisbamate

SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that it was granted special status by the U.S. Food and Drug Administration (FDA) for carisbamate for the management of patients with infantile spasms (IS), a form of epilepsy associated with increased risk of death or mental retardation.

20 Apr 2012

Palatin, AstraZeneca initiate second AZD2820 phase I trial in obesity

Palatin Technologies, Inc. today announced that a second phase I clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist under development for the treatment of obesity, has commenced.

20 Apr 2012

Perspectives: What is the role for comparative effectiveness research?

The Journal of the American Medical Association devoted this week's issue to the topic of comparative effectiveness and how it should be used in medicine.

19 Apr 2012

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy.

19 Apr 2012

New studies on personalized lung cancer treatment presented at 3rd ELCC

Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva.

19 Apr 2012

Perampanel drug may significantly reduce seizure frequency

A new type of anti-epilepsy medication that selectively targets proteins in the brain that control excitability may significantly reduce seizure frequency in people whose recurrent seizures have been resistant to even the latest medications, new Johns Hopkins-led research suggests.

19 Apr 2012